# The State of AI in Pharma 2027

Report · Edition 01

Canonical: https://www.katalyzeai.com/reports/state-of-ai-in-pharma-2027

What are the rules? Where can you trust AI?

Pharmaceutical manufacturing and quality, the evidence and workflows they depend on, and the opportunities and limits of AI.

## Three findings, open to read.

### Why do deviation investigations take so long?

A survey of 13 companies found about 18.1 hours of activity inside 29 calendar days for a minor deviation. The report looks at where the days go.

Calendar days for a minor deviation: 29 days

BioPhorum survey of 13 member companies, 2017

### What do AI-containing submissions tell us about pharma?

The figure counts submissions that contain AI. It is not a count of approved AI systems, and it is not evidence of adoption in manufacturing plants.

Submissions to FDA with AI components: 1,000+

FDA, with the centers and the reporting period the figure covers

### Where can you trust AI?

The report separates a person being involved from a review that is effective, and sets out what to record of what was reviewed and approved.

Part 1 · Where can you trust it?

Human involvement is not the same as effective review.

- 04 What is established and what is still proposed entering 2027: In the report
- 05 The checks a digitized record has to pass before it is used: In the report
- 06 What to establish before expanding AI use in 2027: In the report

## Three parts: the rules, the evidence, the work.

Each chapter sets out what is established, where AI may help, and what remains to be demonstrated.

### What AI-containing submissions tell us about pharma

Introduction

- Regulatory status at a glance

### The regulatory position entering 2027

Part 1

- What FDA and European regulators expect of AI
- Where can you trust it?

### The evidence foundation

Part 2

- Pharmaceutical document digitization: accuracy, integrity, and review
- Operational context: grounding AI in pharmaceutical evidence

### Investigation and process improvement

Part 3

- Deviation investigations: workload, evidence, and judgment
- Yield optimization: from measurement to controlled change

### What teams should establish before expanding AI use in 2027

Closing

## The rules, the evidence and the work, in one report.

[Get the Report](https://www.katalyzeai.com/reports/state-of-ai-in-pharma-2027#report)

## About the report.

### Who is the report for?

Manufacturing and quality teams in pharma who are deciding where AI goes next, and what it has to show first.

### What is the report based on?

What FDA and European regulators have published, published industry surveys, and Katalyze's own guides, each cited where it is used.

### Is the report free?

Yes. A copy is sent to the address given.

### What is my email address used for?

To send the report, with a follow-up about it. The newsletter goes only to those who ask for it.
